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Rational steering of insulin binding 
specificity by intra-chain chemical 
crosslinking
Jitka Viková1, Michaela Collinsová1, Emília Kletvíková1, Miloš Buděšínský1, Vojtěch Kaplan1, 
Lenka Žáková1, Václav Veverka1, Rozálie Hexnerová1, Roberto J. Tarazona Aviñó1, 
Jana Straková1, Irena Selicharová1, Václav Vaněk1, Daniel W. Wright2, Christopher J. Watson2, 
Johan P. Turkenburg2, Andrzej M. Brzozowski2 & Jiří Jiráček1
Insulin is a key hormone of human metabolism with major therapeutic importance for both types 
of diabetes. New insulin analogues with more physiological profiles and better glycemic control 
are needed, especially analogues that preferentially bind to the metabolic B-isoform of insulin 
receptor (IR-B). Here, we aimed to stabilize and modulate the receptor-compatible conformation 
of insulin by covalent intra-chain crosslinking within its B22–B30 segment, using the CuI-catalyzed 
Huisgen 1,3-dipolar cycloaddition reaction of azides and alkynes. This approach resulted in 14 
new, systematically crosslinked insulin analogues whose structures and functions were extensively 
characterized and correlated. One of the analogues, containing a B26–B29 triazole bridge, was highly 
active in binding to both IR isoforms, with a significant preference for IR-B. Our results demonstrate the 
potential of chemistry-driven modulation of insulin function, also shedding new light on the functional 
importance of hormone’s B-chain C-terminus for its IR-B specificity.
Insulin is a small protein hormone composed of chain A (21 residues) and chain B (30 residues), and it exerts its 
biological effects by binding to the ~340 kDa tyrosine-kinase type insulin receptor (IR). Insulin plays a central 
role in mammalian biology1, and has a widespread impact on blood glucose levels, lipid and protein metabolism, 
cell growth/differentiation, and life span2. The IR ectodomain comprises two α -subunits and two β -subunits 
linked by S-S bonds. The α -subunits assure hormone binding, whereas β -subunits transduce the signal to the 
cytoplasmic tyrosine-kinases of the IR3,4. Insulin signaling pathways are complex due to the existence of two IR 
isoforms: IR-A, and the alternatively spliced IR-B, which has 12 additional amino acids at the C-terminus of the 
α -subunit5, within the so-called α CT-segment. The IR-isoform expression pattern is tissue specific6–8, with IR-B 
being most abundant in the main insulin glycemic-response tissues (e.g., IR-B accounts for 90–95% of all IR in 
liver), but being also present in muscles and adipose tissue. The IR-A isoform dominates in brain, fetal and cancer 
tissues, and is also a relatively good receptor for the growth factors IGF-2 and IGF-1. These characteristics make 
IR-B the predominantly ‘metabolic’ type of the IR, whereas IR-A can act in other, more mitogenic, signaling 
pathways.
Defects in insulin bio-availability, or impaired IR signaling, may result in different pathological conditions, 
such as diabetes (type 1 – insulin dependent; type 2 – insulin independent)9,10, cancers11 and Alzheimer’s disease12.
Extensive structural and functional characterization of insulin allowed rational optimization of some of its 
pharmacodynamic properties. It has focused on two, rather contrasting tasks: (i) the delivery of fast-acting insu-
lins (with a highly monomeric character or with rapid dissociation from the hexameric form prevalent in insulin 
storage), and (ii) the development of long-acting insulins. The second task tries to minimize the frequency of 
exogenous delivery of the hormone to diabetics through restoration and mimicking of the physiological profile of 
insulin-dependent glycemic control. Under physiological conditions, approximately half of the insulin secreted 
from the pancreas to the portal vein is used by the liver-abundant IR-B, resulting in a predominantly hepatic to 
peripheral action of this hormone. In contrast, exogenously delivered insulin interacts primarily with the homol-
ogous IR-A:IR-B distribution in the peripheral tissues, prior to inducing its normal liver response13. Because the 
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excessive exposure of nonhepatic tissues to insulin in diabetics can lead to a plethora of significant side effects, the 
development of novel insulins with high IR-B and low IR-A specificities is highly desirable.
Progress in rational mimicking of the physiological profile and action of insulin has been hampered by lack 
of 3D structures of its complex with IR. However, the long-awaited structural insight into insulin:IR initial bind-
ing events has recently been attained14. Surprisingly, the structures of insulin in complexes with some IR con-
structs showed that the main interaction of the hormone with the N-terminal L1 domain of the IR α -subunit 
(the main hormone binding site) is not direct, but is mediated extensively by the α CT-segment. Remarkably, the 
α CT-segment moves in this process across the whole ectodomain, and is anchored on the L1-surface of the neigh-
boring α -subunit. Importantly, these first insulin-IR complex structures also shed light on the ‘active’ conforma-
tion of insulin B22–B30 chain15, which has to undergo a conformational change on the receptor. Interestingly, 
some of our parallel efforts to decipher the ‘active’ B22–B30-fold by extensive chemical modifications yielded 
highly active insulin analogues16. The main common signature of these analogues was the so-called B26-turn 
(a particular bend of the B25–B30 chain), combined with the structural conservation of the invariant and impor-
tant PheB24 site17,18. The overall conformational features of this structural convergence were supported by the 
structures of the insulin:IR complexes. Moreover, we also showed that the IR-complex-compatible B26-turn-like 
conformation of the B25–B30 insulin chain can be generated by a single natural mutation at the B26 site (e.g., Tyr 
to Asn)19, highlighting further the importance of the B26 region for an effective insulin-IR interaction (Fig. 1). 
This work also indicates the potential of protein chemistry as an important tool in insulin studies that can provide 
an independent and reliable insight into insulin structure and function.
Experience with the structural and functional manipulation of insulin, underpinned by the progress in insu-
lin:IR research, encouraged us to probe an induction of the active structure of this hormone by the incorporation 
of a covalent crosslink within its B22–B30 chain, which would result in a stable B26-turn-like conformation. 
However, the aims of this research evolved along the promising progress of this research: the initial goal of cap-
turing a ‘mechanistic snapshot’ of insulin conformation was transformed into the aim of design and delivery of 
IR isoform-specific analogues.
To achieve the stabilization of a specific conformation of the hormone, we developed the strategy of inserting 
a covalent bridge between specific sites at the B24–B30 C-terminus of the insulin B-chain, i.e., an intramolecular 
side-chain:side-chain crosslinking. The CuI-catalyzed Huisgen 1,3-dipolar cycloaddition reaction of azides and 
alkynes20,21 was employed in this process. This biorthogonal reaction, also called ‘click chemistry’, leads to the 
formation of 1,4-disubstituted 1,2,3-triazoles. This reaction has become widely used22 in organic, medicinal and, 
especially, peptide chemistry because 1,2,3-triazoles present a motif with structural and electronic characteristics 
similar to those of the peptide bond. Moreover, 1,2,3-triazoles have found applications in peptide cyclizations, 
induction of some secondary structures in peptides, especially β -turns23,24, β -hairpins25, helical structures26–28 or 
mimics of disulfide bonds29. This approach was recently used to replace the A7-B7 inter-chain disulfide bond in 
insulin, but it yielded misfolded and inactive protein30. A succesfull incorporation of a triazole crosslink into the 
full protein structure (on an analytical scale) was reported by Neumann et al.31, who encoded precursor amino 
acids into the sequence of calmodulin, with the subsequent in vitro formation of the crosslink. Here, we selected 
CuI-catalyzed cycloaddition to bridge specific sites within the insulin B-chain B24–B30 C-terminus (intra-chain 
crosslinking), using specific amino acids with azido and alkynyl side chain groups as precursors. To our knowl-
edge, the research reported here is a unique example of the use of triazole-forming click chemistry within the 
same native protein main-chain to successfully steer its structure and function.
This work yielded 14 novel, systematically crosslinked insulin analogues, which structures and functions were 
extensively characterized. Most interestingly, one of the analogues, insulin with a B26–B29 triazole-bridge, was 
highly active in binding to both isoforms of IR, with a significant preference for IR-B. Our results indicate the 
Figure 1. An overlay of human insulin structures that were key templates in this work. All A chains (not 
relevant here) are in a translucent white; the wild-type B-chain (pdb 1mso) is in coral; the B-chain insulin 
structure attained in the complex with IR (pdb 4oga) is in blue; and the B-chain of one of the representative 
B26-turn-containing analogues (AsnB26-insulin, pdb 4 ung) is in gold.
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potential of chemistry-driven modulation of insulin function, and also shed light on the functional importance 
of the B-chain C-terminus of the hormone for its IR-B specificity.
Results
Synthesis of the analogues. Insulin analogues 1–14 were prepared according to the previously described 
protocol16,32 for the enzymatic semisynthesis starting from des(B23–B30)octapeptide-insulin (DOI) and cyclic 
(crosslinked) octapeptides 1b–14b, respectively. In the case of some less soluble cyclic peptides, the semisynthesis 
was performed according to the slightly modified protocol by Nakagawa and Tager33. The solid-phase synthesis 
of the linear insulin B23–B30 octapeptide precursors 1a–14a proceeded readily and with good yields. These 
precursors contained azido- and alkynyl-side chain amino acids at different sites as precursors for CuI-catalyzed 
cycloaddition. Cycloadditions were performed using two methods. Method A was usually completed after 30 min, 
and the cyclic products were easily purified by HPLC. However, cyclization of the linear B23–B30 precursor 14a 
for insulin analogue 14 also yielded a 5-hydroxy-triazole cyclic octapeptide byproduct that was difficult to sepa-
rate. This issue was overcome by the use of method B by Chen et al.34; this process uses the TBTA copper ligand 
and an inert atmosphere in the dark to minimize the formation of hydroxylated triazoles.
The schematic structures of insulin analogues (1–14), together with their binding affinities for IR (for the 
analogue 8 also for the IGF-1R), are summarized in Fig. 2 and in Table 1. The binding curves are shown in 
Supplementary Fig. S1–S4.
Design strategies for intra-chain crosslinking of insulin analogues. The original aim and strat-
egy of this research was to probe whether the insulin-active-like conformation (observed in its IR complex and 
highly active analogues), i.e., bend of the B23–B30 chain around B25–B26 sites, can be mimicked, stabilized and 
exploited by the incorporation of a crosslink (covalent bridge) within this region of the hormone. The main steric 
parameters were as follows: (i) the positions of the propargylglycine (Prg) and azidonorleucine/azidonorvaline 
(Nle(ε N3)/Nva(δ N3)) precursors within the B23–B30 chain, (ii) the length of the crosslinked protein main chain, 
(iii) the chirality or the precursors, and (iv) the position of the triazole ring (i.e., up- or down-stream of the main 
chain). The chiralities and side-chains related restraints of the B24 and B29 sites were also altered, or liberated, by 
Gly substitutions in some analogues.
These strategies resulted in 14 analogues that may be grouped into two classes that reflect certain corre-
lations between their affinities and the type of click-crosslinking (Fig. 2). All class 1 analogues (1–7) have 
triazole-containing linkers with eight backbone atoms, while all class 2 analogues (8–14) have triazole-containing 
linkers with 7 backbone atoms.
Class 1: i + 5/i + 4 crosslinked non-active analogues. The long (i + 5) separation between clicking groups was first 
chosen to assure a wide and gentle sweep of the main chain conformation, i.e., to minimize its structural strain, 
and to allow the B23–B30 chain to attain a conformation similar to the B26-like turn, or to the bend of the hor-
mone observed in the insulin:IR complexes. However, the IR-A affinities of all of B24–B29 crosslinked analogues 
1–5 were negligible (< 1%) (Table 1), regardless of the R/S permutations of the Cα chirality of the crosslinking 
precursors (propargylglycine and azidonorleucine).
Subsequently, the span of the crosslinked main chain was shortened to i + 4, and the anchor site of the result-
ing triazole ring was moved from the B24 to the B25 site. However, as in the i + 5 case, analogues 6 and 7 were 
inactive.
Class 2: i + 3/i + 2 crosslinked active analogues. Subsequently, the impact of shorter i + 3 cyclizations between 
the B26–B29 sites was investigated. The anchor site for the first (sequence-wise) click precursor site was moved 
further to position B26, and the azidonorleucine click precursor was substituted here by a shorter azidonorvaline 
acid to facilitate tighter crosslinking. Analogues 8 and 9 that were created during this step differed in the reversed 
positions of the propargyl and azido precursors; this change was implemented to probe the effect of the position 
of the triazole ring within a particular analogue on its structure and function. This approach yielded the highly 
IR-A potent (208 or 226% in two independent measurements) analogue 8. The move of the triazole position to a 
location near the B26 site in analogue 9 lowered its IR-A affinity to ~62%.
Because the B24–B29 to B26–B29 shift of the crosslink bridge yielded the high IR-A affinity analogue 8, pos-
sible larger gains in receptor affinity upon moving the crosslink further towards the C-terminus of the B-chain 
were expected and investigated by the B27–B29 (i + 2) cyclization of insulin. However, this shortening of the 
crosslinked sequence lowered the affinity of the resulting analogue 10 to 61%.
Analogues 8–10 indicated possible superiority of the i + 3 over i + 2 cyclization. This was examined in the 
next analogue, 11, in which the azido precursor at B27 was clicked with propargyl at B30. The side chain-free 
GlyB29 was used here instead of the wild-type LysB29 to avoid possible steric interference in the cyclization reac-
tion. The full insulin IR-A affinity (103%) was regained in this analogue.
The class 2 crosslinked insulins also contain a sub-group of analogues with an achiral Gly at the B24 site 
(GlyB24-series). This substitution resulted from an accidental PheB24Gly replacement during one of the prepa-
rations of the octapeptide precursor for analogue 10. Surprisingly, this error generated a 148% IR-A potent ana-
logue 12, with more than double the affinity compared to its ‘correct’ PheB24 homologue 10. This result prompted 
the incorporation of GlyB24 into the most active insulin in this series, analogue 8, but the resulting analogue 13 
showed a potency of only 15%.
The last insulin of this series, analogue 14, was an attempt to enhance further the affinity of analogue 12, by 
the addition of the methylation of the B26 NH-main chain atom previously (and successfully) exploited by us. 
This modification in the N-MeAlaB26 analogue (truncated also and amidated at the B26 site) yielded a highly 
active (465%) form of the hormone16. However, this more extensive combination of the main- and side-chain 
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modifications together with the B27–B29 crosslink and the GlyB24 mutation was not additive, and practically 
abolished the affinity of analogue 14.
IR-B specificity and IGF-1R binding of crosslinked insulin analogues. The analogues with signifi-
cant IR-A affinities were selected and tested further for their binding to the IR-B isoform and to the IGF-1R recep-
tor. Most interestingly, the IR-A highly active (~217%) analogue 8 also showed a potency of more than five times 
(~567%, i.e. 515 or 620% in two independent measurements) for the IR-B isoform. The swap of the crosslink 
precursor sites in 8 lowered the IR-B/IR-A affinities of the resulting analogue 9 to 73% and ~62%, respectively, 
indicating the sensitivity of the IR-B specificity to the position of the triazole group, and, likely, to the particular 
conformation of this B26–B29 crosslink. Moreover, the GlyB24-containing analogue 12 with 148% IR-A affinity 
was also equipotent against IR-B (129%).
The significance of the desirable IR-A/B affinities of analogue 8 was amplified further by its approximately 
four times lower potency towards IGF-1R, making this insulin and its chemical scaffold a promising molecular 
platform for future clinically-oriented studies of this hormone.
Figure 2. Schematic representation of intra-chain crosslinked octapeptides in the insulin analogues 1–14 
produced in this work. Black dots (⚫ ) indicate the Cα carbons in the backbone and blue dots (⚫ ) indicate 
CH2 atoms in the linkers. Dashed lines indicate alternative chirality. G in red indicates the positions of Gly 
mutations. mA in red indicates the position of N-methylated alanine. The binding affinities (in %) relative to 
native insulin are shown to the right. Triazole rings are shown as pentagrams with blue nitrogen atoms. nd 
stands for not determined. DOI is des(B23–B30)octapeptide-insulin.
www.nature.com/scientificreports/
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Structure-function correlations of crosslinked insulin analogues. The evidence for the structural 
impact of the crosslinking in the analogues reported here comes from three crystal (analogues 2, 10, 11) and 
two NMR (analogues 8, 12) structures. Because the B24–B30 chain of insulin undergoes a large conformational 
change upon IR binding, the structures were also superimposed on the ‘active’ form of the wild-type insulin in its 
IR complex to provide some general structural context15 (Fig. 3). However, to obtain a more realistic assessment 
of the structural impact of the crosslink on the insulin-embracing IR environment, only the B24–B30 chain of 
each analogue was superimposed on the receptor-complexed hormone. The conformation of the insulin PheB24 
main and side chains in the IR complex (structural and functional ‘pivot’ of the IR-bound hormone) was the main 
overlap target (Fig. 4).
Analogue 2 (cyclo[G23-Prg-FYTP-Nle(εN3)-T30]-insulin). The B24–B29 linker spans a long stretch of 
the B-chain, strongly affecting the local and global conformation of this inactive analogue (Fig. 3a). First, the 
linker significantly increases the mobility and disorder of this part of insulin, and it is well defined in only one of 
four independent hormone molecules in the crystal, with one B-chain untraceable after CysB19. Although the 
triazole part of the linker (in the most ordered molecule) occupies roughly the PheB24 site of the native insulin, 
the B23–B30 main chain is very distorted (e.g. 3.8 Å difference at the B25 Cα atoms from the native hormone). 
Protein 
Position and type of triazole 
bridge
Kd ± S.E. 
[nM] (n) for 
human IR-A
Relative binding 
affinity for human 
IR-A (%)a
Kd ± S.E. 
[nM] (n) for 
human IR-B
Relative binding 
affinity for human 
IR-B (%)
Kd ± S.E. [nM] 
(n) for human 
IGF-1R
Relative binding 
affinity for human 
IGF-1R (%)
Human insulin 0.20-0.43b 100c,d,e,f,g,h 0.67 and 0.31i 100j,k 292 ± 31 (3) 0.08 ± 0.01
Human IGF-1 ndl nd nd nd 0.24 ± 0.05 (5) 100 ± 21
Cyclo[GB23-d-Prg-FYTP-
Nle(ε N3)-TB30]-insulin (1)
92.0 ± 6.1 (4) 0.33 ± 0.02c nd nd nd nd
Cyclo[GB23-Prg-FYTP-
Nle(ε N3)-TB30]-insulin (2)
226 ± 16 (4) 0.13 ± 0.01c nd nd nd nd
Cyclo[GB23-d-Nle(ε N3)-
FYTP-Prg-TB30]-insulin (3) 59.6 ± 8.2 (4) 0.50 ± 0.07
c nd nd nd nd
Cyclo[GB23-d-Prg-FYTP-d-
Nle(ε N3)-TB30]-insulin (4)
126 ± 16 (3) 0.29 ± 0.04d nd nd nd nd
Cyclo[GB23-d-Nle(ε N3)-
FYTP-d-Prg-TB30]-insulin (5) 214 ± 50 (3) 0.17 ± 0.04
d nd nd nd nd
Cyclo[GB23F-Prg-YTP-
Nle(ε N3)-TB30]-insulin (6)
32.9 ± 2.6 (3) 0.82 ± 0.06e nd nd nd nd
Cyclo[GB23F-d-Prg-YTP-
Nle(ε N3)-TB30]-insulin (7)
519 ± 104 (3) 0.05 ± 0.01e nd nd nd nd
Cyclo[GB23FF-Nva(δ N3)-TP-
Prg-TB30]-insulin (8)
0.19 ± 0.02 
(3) 
0.13 ± 0.01 
(3)
226 ± 24f  
208 ± 16e
0.13 ± 0.02 
(3) 
0.05 ± 0.01 
(5)
515 ± 79j 
620 ± 124k 1327 ± 461 (3) 0.02 ± 0.01
Cyclo[GB23FF-Prg-TP-
Nva(δ N3)-TB30]-insulin (9)
0.56 ± 0.03 
(3) 62.5 ± 3.3
g 0.92 ± 0.12 
(4) 73 ± 10 nd nd
Cyclo[GB23FFY-Nva(δ N3)-P-
Prg-TB30]-insulin (10)
0.33 ± 0.01 
(3) 61.0 ± 1.8
h nd nd nd nd
Cyclo[GB23FFY-Nva(δ N3)-
PG-PrgB30]-insulin (11)
0.36 ± 0.06 
(4) 103 ± 17
d nd nd nd nd
Cyclo[GB23GFY-Nva(δ N3)-P-
Prg-TB30]-insulin (12)
0.29 ± 0.06 
(3) 148 ± 31
f 0.52 ± 0.08 
(3) 129 ± 20 nd nd
Cyclo[GB23GF-Nva(δ N3)-TP-
Prg-TB30]-insulin (13)
1.76 ± 0.19 
(4) 15.3 ± 1.7
e nd nd nd nd
Cyclo[GB23GF(NMe)A- 
Nva(δ N3)-P-Prg-TB30]-
insulin (14)
106 ± 7 (3) 0.19 ± 0.01h nd nd nd nd
Table 1.  Crosslinked insulin analogues and their binding affinities. The analogues were cyclized at different 
positions of the C-terminal octapeptide (B23–B30) of the B-chain using specific amino acid precursors: l- or 
d-propargylglycine (Prg or d-Prg, respectively), l- or d-azidonorleucine (Nle(ε N3) or d-Nle(ε N3), respectively) 
and azidonorvaline (Nva(δ N3)). Other non-natural substitutions (G for glycine and (NMe)A for N-methyl-
alanine) incorporated into C-terminal octapeptides are also shown. The Kd values and the relative binding 
affinitiesa of human insulin and insulin analogues for isoform A (IR-A) and isoform B (IR-B) of the human 
insulin receptor or for the IGF-1 receptor (IGF-1R) are also given. Each value represents the mean ± S.E. of 
(n) independent measurements. aThe relative receptor binding affinity (potency) is calculated as Kd of human 
insulin/Kd of analogue) × 100. bDifferent measurements in the range 0.20-0.43 nM. cRelative to the human 
insulin Kd value of 0.30 ± 0.01 (n = 4, 100 ± 3%). dRelative to the human insulin Kd value of 0.37 ± 0.03 (n = 5, 
100 ± 8%). eRelative to the human insulin Kd value of 0.27 ± 0.04 (n = 5, 100 ± 15%). fRelative to the human 
insulin Kd value of 0.43 ± 0.01 (n = 5, 100 ± 2%). gRelative to the human insulin Kd value of 0.35 ± 0.06 
(n = 4, 100 ± 17%). hRelative to the human insulin Kd value of 0.20 ± 0.02 (n = 5, 100 ± 10%). iTwo different 
measurements. jRelative to the human insulin Kd value of 0.67 ± 0.08 (n = 4, 100 ± 12%). kRelative to the 
human insulin Kd value of 0.31 ± 0.07 (n = 6, 100 ± 23%). lNot determined.
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However, it seems that not the increased dynamics of the B20–B30 chain but a peculiar conformation of the large 
B24–B29 ‘macrocycle’ of this analogue abolishes its IR-A affinity. Any modeling of analogue 2 (or its B24–B30 
part only) on the insulin:IR complex leads to large clashes of the B24–B29 loop with the L1 surface of the receptor, 
or its α CT segment. This extensive steric hindrance occurs despite the general, and reasonable, match between 
the triazole moiety and the PheB24 site on the L1 domain. However, it is also possible that the polar character 
of the electron-rich triazole ring is incompatible with the PheB24 hydrophobic binding pocket (Asn15, Leu37, 
Phe39 and Phe714) on the IR. Therefore, the lack of any IR-A affinity of analogue 2 likely can result from both the 
disruption of the B24 site (on insulin and IR), and an unfavorable conformation of the large B24–B29 macrocycle 
on the α CT-L1-domain.
Analogue 10 (cyclo[G23FFY-Nva(δN3)-P-Prg-T30]-insulin). The B24–B29 to B27–B29 shift of the 
crosslinking bridge almost restored the IR-A affinity (61%) of this analogue. Interestingly, the B27–B29 linker 
does not significantly affect the overall or local (e.g., B20–B26) insulin structures (Fig. 3b); the linker allows 
even the formation of typical insulin dimers with usual dimer-interface hydrogen bond patterns. Any structural 
variability observed here is characteristic for all other known insulin oligomers. However, in contrast to 2, the 
B24–B30 chain of analogue 10, when modeled on the B24 site of IR-bound insulin (not shown), can, somehow, 
be accommodated on the L1 surface, and its further reconfiguration will diminish clashes with the α CT-segment. 
Therefore, the shortening of the crosslinked sequence and its shift towards the very end of the B-chain in analogue 
10 alleviates the conformational stress observed in 2, allowing likely a more effective contribution of the B24–B26 
part of the B-chain towards its interaction with IR-A.
Analogue 11 (cyclo[G23FFY-Nva(δN3)-PG-Prg30]-insulin). The full IR-A affinity (103%) was restored in 
analogue 11 by expansion of the crosslink from position B29 to the B30 site. The LysB29→ Gly mutation removed 
also possible side-chain interference at this site. In contrast to analogue 10, the crosslinked-loop is not in the 
plane of the B-chain; instead, it bulges sideways to accommodate the longer linker (Fig. 3c). However, as in 10, the 
cyclization within the end of the B-chain did not interfere with the dimeric properties of 11, allowing this ana-
logue to maintain a regular dimer interface, and to form a typical R6 hexamer. Moreover, simple modeling of the 
B24–B30 segment of 11 on the insulin in the IR-A complex leads to an even more optimum conformation of the 
B27–B30 crosslinked-loop of this analogue in relation to the L1-domain and the α CT-segment of the receptor. In 
this model (not shown), the C-terminal part of the B-chain in 11 passes under the α CT-segment and folds back 
to embrace that segment on the other side of the α CT helix.
Analogue 12 (cyclo[G23GFY-Nva(δN3)-P-Prg-T30]-insulin). The NMR structure of this ana-
logue revealed the down-register shift of the B25–B30 insulin chain, observed in previously described 
GlyB24-containing analogues. All converged structures of 12, measured at acidic pH, are shown in Supplementary 
Fig. S5, and a representative structure (at pH 1.9) is shown in Fig. 3d. They confirm the observations that the emp-
tying of the PheB24 cavity in insulin by PheB24Gly mutation is structurally preserved by the pull down of PheB25 
into the B24 site18,35. However, the mimicking of the PheB24 site by PheB25 is less perfect in analogue 12 than in 
other similar (i.e., PheB24-‘empty pocket’) analogues, and the B25–B30 chain departs sharply from the core of the 
molecule at ca. 90° angle. The modeling of the standalone B24–B30 chain on the insulin-IR complex (not shown) 
results in the arrangements similar to those found in analogues 10 and 11. Analogue 12 confirms also that high 
IR-affinity does not have to be compromised even in very substantially engineered insulins, if the ring in the B24 
site is hydrophobic.
Analogue 8 (cyclo[G23FF-Nva(δN3)-TP-Prg-T30]-insulin). The B26–B29 crosslink with the triazole moi-
ety close to the B29 site yielded analogue 8 with 208–226% affinity for IR-A, and, more importantly, 515–620% 
affinity for the IR-B isoform. As this analogue resisted crystallization, NMR structures were determined in both 
acidic (pH 1.9) and alkaline (pH 8.0) environments. Supplementary Fig. S6 shows all converged NMR structures 
of 8 at pH 1.9 and 8.0. The structures are similar and homologous to native insulin up to the PheB24 site, with 
its phenyl moiety still occupying the PheB24 pocket. However, the remaining B-chain is fully detached from 
the core of the hormone from the B25 site (exemplified, for example, by the ~16 Å separation between the B25 
Cα atoms of the native hormone and analogue 8). The representative NMR structure of 8 at pH 8.0 is shown 
in Fig. 3e. Although the conformation of the B26–B30 chain in 8 does not exactly resemble the B26-turn- or 
AsnB26-bend-like ‘active’ folds, it confirms the trend and scale of the detachment of the B-chain observed in these 
‘active’ analogues. The overall conformation of B26-turn-, AsnB26-analogues and analogue 8 B24–B30 chains can 
be matched by an ~180° rotation about the psi angle of PheB25 in 8 (not shown). Interestingly, the i + 3 crosslink 
does not cause any bulge of the B-chain (as observed in the i + 3 crosslink of analogue 11); instead, this crosslink 
is well accommodated in 8 within the plane determined by the bend of the B-chain.
The structural origins of the high IR affinities in analogue 8 may result, at least partly, from a peculiar and 
unique conformation of its B24–B30 segment. Firstly, the modeling of only this part of 8 on its equivalent in 
the IR-complexed insulin (Fig. 4) gives the best fit of all analogues studied here; both chains show a remarkably 
similar fold and direction if they are matched at the B24 site. Secondly, the rotamer of PheB24, which changes 
significantly upon insulin binding to IR15, is most similar between analogue 8 and IR-complexed insulin.
Discussion
The research reported here provides the first evidence that the intra-chain CuI-catalyzed cycloaddition (‘click’) 
chemistry can be used for a rational steering of protein functionality. A series of systematic chemical crosslinks 
spanning different sites of insulin’s main-chain led to the development of analogue 8 with high IR affinity, and, 
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Figure 3. Comparison of range of conformations of the B-chain observed in the structures of the wild-
type human insulin (white), insulin in the IR complex (coral), and in the analogues discussed in this 
work (yellow): (a) 2, (b) 10, (c) 11, (d) 12, and (e) 8. The carbon atoms of the crosslinks are in green, and the 
nitrogens in blue; crosslinked sites are labeled in red; in (c), the C-terminal carboxyl group (part of one crosslink 
precursor) is also given. The wide spectrum of crosslink-generated conformations of insulins is shown in (f ) 
by superposition of the analogues given in (a–e). The red letters at the analogues correspond to the structures 
in panels (a–e); wild-type (WT in white, pdb 1 mso) and IR-complexed insulin (coral, pdb 4 oga) are also given 
with all B7–B19-helices shown in white.
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more importantly, with a significant selectivity for the IR-B isoform that is responsible for the insulin main 
hepatic response.
The structure-function correlations and trends observed in these analogues indicate that the main part of 
the B-chain responsible for an efficient crosslinking covers the B26–B29 or B27–B29/B30 region of insulin. Both 
i + 3/i + 2 main-chain separations of click precursors are also efficient in this process, with the i + 3 B26–B29 
crosslink generating both high affinity and significant IR-B receptor selectivity. Furthermore, the particular posi-
tion of the triazole moiety within the crosslink seems to play an important role in this process as well. All active 
analogues showed a preference for distal positioning of the triazole in the linker, i.e. with the triazole group closer 
to the C-terminus of the B-chain. For example, the swap of the triazole anchoring from the B29 site to the B26 site 
in analogues 8 and 9, respectively, resulted in a decrease of more than three times in IR-A affinity and a more than 
seven times lower IR-B affinity. This indicates that inserting triazole-containing linkers into the insulin B-chain 
not only affects the 3D fold but also creates new sub-structures that are involved in the direct interactions with 
the IR.
However, despite some clear structural and functional trends, the actual structural origins of higher affinity of 
any of these analogues are not unambiguous. This is not surprising as the large-scale of the conformational activa-
tion of insulin B24–B30 chain upon binding to IR prevents meaningful, direct superposition of the analogues on 
the native insulin in the IR-A complex. However, modeling the B24–B30 segments with the IR-complexed insulin 
provides valuable insight into the role of the crosslink in generation of different affinities. For example, a better 
accommodation of the B24–B30 chain between the L1-surface and α CT-segment correlates well with the higher 
affinity of an analogue, although further, small structural tuning of the modelled B24–B30 chains is certainly 
required for their more effective tethering into the IR. The role of a particular rotamer of PheB24 (observed in the 
insulin:IR complex)15 may be crucial in this process as well. Nevertheless, the crosslink-induced macrocycles in 
the B26–B30 regions of the analogues provide a novel, adaptable, but ultimately quite rigid (i.e., triazole group) 
scaffold for the putative interactions with both the L1-surface and α CT-segment.
The structural reasons for the remarkably high (~567%) affinity of analogue 8 for IR-B require further studies, 
and are currently unclear; there are no obvious, dominating putative interactions between the modeled B25–B30 
chain of analogue 8 and the α CT-segment. However, the site of a 12-amino acid insertion (exon11) and hence the 
extension of the α CT-polypeptide in the IR-B isoform (Pro716) lies just above the PheB25-TyrB26 region of insu-
lin. Therefore, it cannot be excluded that the longer α CT-B-segment does not simply follow the conformation of 
α CT-A (i.e., departing from the L1 domain). Instead, this segment might adopt a different conformation, which, 
for example, would be more engaged with the (possibly rearranged) B26–B29 crosslinked loop of analogue 8. 
These new (but still unobserved) IR-B:8 specific contacts may involve both the triazole ring and insulin B27–B30 
main/side-chains of this structurally stable and new ‘macrocycle’ within this hormone. The importance of the 
position/orientation of the triazole ring for the interaction with IR is also evident from the lower binding affinities 
of 9 (a homologue of 8), in which the triazole was placed closer to the B26 site. Interestingly, it was suggested that 
the almost four-times IR-B specificity of the triple HisA8, HisB25, and GluB27 mutant of insulin (15% for IR-A, 
57% for IR-B) can originate from the putative intra-molecular hydrogen bond between the side chains of the 
mutated B25–B27 sites36. Therefore, it cannot be excluded that the crosslink in 8 may reflect similar, but firmer, 
covalent intra-molecular stabilizing interactions.
In summary, we show here that the combined application of organic and protein chemistry to the B26–B30 
‘IR-irrelevant’ part of the hormone modulates its functionality, and transforms this region into a structural ele-
ment that confers high affinity and specificity to insulin. The incorporation of specific triazole crosslinks into 
the C-terminal part of the B-chain of insulin can change the conformation of this insulin segment, initiating its 
detachment from the core of the insulin molecule. Importantly, this modification provides new, chemical and arti-
ficial protein sub-structures that interact with IR and modulate insulin affinity. Therefore, the triazole-containing 
Figure 4. Two views of a putative fold of the B24–B30 crosslink-containing chain of the IR-B-specific 
analogue 8 modeled on the insulin:IR complex structure, assuming an invariant conformation of PheB24. 
(a) View from the top of the IR L1 domain and (b) from the side (edge) of the IR L1 domain. Insulin A and B 
chains are in gold and coral, respectively, and the α CT IR-A segment in violet. The B24–B30 segment of 8 is 
in yellow with triazole nitrogens in blue. Red asterisk indicates the insertion site (716) of the exon 11-coded 
additional 12 amino acids of the α CT segment in the IR-B isoform.
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crosslinks (or other suitable chemical moieties) in the insulin B-chain C-terminus could become promising syn-
thetic platforms for the rational design of receptor-selective insulins, especially when the engineered part of insu-
lin can be easily attached to the rest of the hormone by enzymatic semisynthesis. The incorporation of specifically 
positioned crosslinks provides a new path for more extensive applications of organic chemistry in engineering of 
the key elements of insulin pharmacophore, and ultimately, an excting possibility for isoform-selective analogues.
Methods
Solid-phase synthesis. Synthetic linear octapeptides (1a–14a), which were derivatives of the C-terminal 
octapeptide of the B-chain of human insulin, were prepared by manual solid-phase synthesis on a 2-chloro-chlo-
rotrityl resin using HBTU/DIPEA reagents and Fmoc-protected amino acids. Fmoc-L-propargylglycine, Fmoc-
D-propargylglycine, Fmoc-L-Nε-azidonorleucine, Fmoc-D-Nε-azidonorleucine or Fmoc-L-Nδ-azidonorvaline 
was incorporated at different positions in the peptides.
Cycloaddition reactions. The cyclic octapeptides 1b–14b were prepared from the linear precursors 1a–14a, 
respectively, by CuI-catalyzed cyclization using two different methods, A and B, as follows.
Method A. The click reactions with octapeptides 1a–13a were performed according to the protocol previously 
published by Isaad et al.37. Briefly, the linear octapeptide (~50 mg, 0.08 mM) was dissolved in a water:tert-butanol 
mixture (2:1, v/v). Then, ascorbic acid (14 eq) and CuSO4.5 H2O (14 eq) were added to a minimum volume of the 
water:tert-butanol mixture. The reaction mixture was briefly stirred, and then the reaction proceeded without 
stirring at RT. The reaction was monitored by HPLC. After the completion of the reaction, the reaction mixture 
was concentrated in vacuum to remove tert-butanol, and the products were isolated from the residual water phase 
and salts using solid-phase extraction on C18-cartridges (Macherey-Nagel) and purified using HPLC.
Method B. The cyclization click reaction with octapeptide 14a was performed differently34. The linear octa-
peptide 14a (~50 mg, 0.08 mM) was dissolved in a degassed mixture of water and tert-butanol (2:1, v/v). Then, 
ascorbic acid (10 eq), CuSO4.5 H2O (5 eq) and TBTA (5 eq) were premixed and added to a minimum volume of 
the degassed water/tert-butanol mixture. The reaction mixture was briefly stirred, and then the reaction pro-
ceeded without stirring at RT in the dark under an inert atmosphere. The next steps were the same as described 
for method A.
Enzymatic semisynthesis. The insulin analogues 1–14 were prepared according to the previously 
described protocol16,32 for the enzymatic semisynthesis starting from des(B23–B30)octapeptide-insulin (DOI) 
and cyclic octapeptides 1b–14b, respectively. In the case of some of the less soluble cyclic peptides, the semisyn-
thesis was performed according to the slightly different protocol published by Nakagawa and Tager33.
Peptide characterization. The precursor peptides (1a, 3a–9a, 11a–14a and 1b–14b) and the resulting 
insulin analogues 1–14 were purified by HPLC. The purity of the products was higher than 95% in all cases. 
Crude linear peptides 2a and 10a were used for the synthesis of their respective cyclic counterparts 2b and 10b 
without HPLC purification. The identity of all precursor octapeptides and resulting analogues was confirmed by 
MS (LTQ Orbitrap XL, Thermo Fisher Scientific, Waltham, MA, USA).
1H and 13C NMR spectra were recorded for octapeptides 1a, 6a and 1b–14b. The NMR spectra were measured 
on a Bruker AVANCE-600 instrument (1H at 600.13 MHz and 13C at 150.9 MHz) with a cryoprobe in H2O:D2O 
(9:1) at 25 °C. A trace amount of dioxane was added as an internal standard, and spectra were referenced using 
δ H (dioxane) = 3.75 ppm and δ C (dioxane) = 69.3 ppm. Structural assignment of proton and carbon signals was 
achieved by combining 1D–1H and 1D-APT-13C-spectra with homonuclear 2D-H,H-COSY, 2D-H,H-TOCSY, 
2D-H,H-ROESY and heteronuclear 2D-H,C-HSQC and 2D-H,C-HMBC spectra. The temperature coefficients of 
the amide NH protons were obtained from additional 1H NMR measurements at 5°, 15° and 35 °C.
Details about the syntheses and analyses of all linear and cyclic octapeptide precursors, the resultant insu-
lin analogues and their chemical structures and analytical data are provided in the Supplementary Information 
(Supplementary text, Fig. S7–S21 and Tables S1–S7).
Determination of NMR structures of analogues 8 and 12. All NMR data were acquired at 25 °C 
from a 0.35 ml sample of 1.5 mmol.l−1 analogue 8 or 12 in a 20% d4-acetic acid (pH 1.9) or in a 25 mmol.l−1 
deuterated-Tris buffer (pH 8.0) containing 5% D2O/95% H2O for analogue 8 only on a 600 MHz Bruker Avance 
spectrometer equipped with a triple-resonance (15N/13C/1H) cryoprobe. A series of homonuclear spectra were 
recorded to determine sequence-specific resonance assignments for the analogues. In particular, 2D TOCSY with 
a 60 ms mixing time, 2D DQF-COSY and 2D NOESY, which was acquired with an NOE mixing time of 200 ms. 
The resonance assignments were deposited in the BMRB database. Residues involved in forming stable backbone 
hydrogen bonds were identified by monitoring the rate of backbone amide exchange in the 2D TOCSY spectra of 
both analogues dissolved in 20% d4-acetic acid/80% D2O. The family of converged structures for both analogues 
was initially calculated using Cyana 2.1. A combined automated NOE assignment and structure determination 
protocol was used to automatically assign the NOE cross-peaks identified in the 2D NOESY spectrum and to pro-
duce preliminary structures38. Subsequently, five cycles of simulated annealing combined with redundant dihe-
dral angle constraints (Redac)39 were used to produce a set of converged structures with no significant restraint 
violations (distance and van der Waals violations < 0.5 Å); these structures were further refined in explicit solvent 
using the YASARA software with the YASARA force field40. The 30 structures with the lowest total energy were 
selected. The family of obtained structures was analyzed using the Molmol41, Protein structure validation software 
suite (PSVS)42 and PyMol. The numbers of observed NOE peaks, additional constraints and structural statistics 
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for the final water-refined sets of structures are shown in Supplementary Tables S8 (analogue 8) and S9 (analogue 
12).
Crystallization, data processing and structure determination. Crystal growth conditions were 
found by the use of an in-house insulin-oriented crystallization screen. Data collection and refinement statistics 
are given in Supplementary Table S10. All crystals were grown by the hanging-drop method at 292K, with 1:1 and 
1:2 protein:well ratios and 5 mg/ml as the main concentration of the analogues in 20 mM HCl. Crystallization 
conditions: (i) analogue 2–0.1 M (NH4)2SO4, 1% (v/v) dioxane, pH 3.0; (ii) analogue 10–0.05 M Li2SO4, pH 3.0; 
and (iii) analogue 11–0.6 M Na2SO4, 0.3 M Tris pH 7.5, 0.6 mM Zn(Ac)2, 0.06% (w/v) phenol. X-ray diffraction 
data were collected at the Diamond Light Source, Didcot (Oxfordshire), UK (analogue 2: station I03 (ADSC 
detector, λ = 0.9763 Å); analogue 10: station I02 (PILATUS detector, λ = 0.9795 Å)), and at the ESRF, Grenoble 
(analogue 11: ID23-2, MAR CCD detector, λ = 0.8726 Å). All crystals were directly immersed in liquid N2 prior 
to data collection at 100 K. Measured reflection intensities for all data sets were indexed, integrated and scaled 
using XDS43,44, HKL2000 (ref. 45) and the CCP4 suite46 implementation of AIMLESS. All structures were solved 
by molecular replacement with Molrep47 using B1–B6 and B24–B30 truncated native human insulin (pdb code 
1mso) as a phasing model. The structures were refined to convergence via the maximum-likelihood method using 
REFMAC48, with additional manual correction using Coot49. The validation of the models in Coot indicated pre-
ferred/allowed ratios (%) of 98.2/1.8, 92.9/7.1 and 99.2/0.8 (outlier) for analogues 2, 10 and 11, respectively. All 
structural comparisons between insulins and analogues were performed using the LSQ fit option for the B9–B19 
helix Cα atoms in Coot. Modeling of the B24–B30 segment of analogue 8 on the insulin:IR complex (pdb code 
4oga) was performed using the best fit of the PheB24 atoms in analogue 8 and complexed insulin. All figures were 
generated using the CCP4mg program50.
Receptor Binding Studies. Human IM-9 lymphocytes (human IR-A isoform). Receptor binding studies 
with the insulin receptor in membranes of human IM-9 lymphocytes (containing only human IR-A isoform) 
were performed and Kd values determined according to the procedure described recently in detail by Morcavallo 
et al.51. Binding data were analyzed using the Excel algorithms specifically developed for the IM-9 cells system in 
the laboratory of Prof. Pierre De Meyts (A. V. Groth and R. M. Shymko, Hagedorn Research Institute, Denmark, 
a kind gift of P. De Meyts) using a method of non-linear regression and a one-site fitting program and taking into 
account potential depletion of free ligand. Each binding curve was determined in duplicate and the final dissocia-
tion constant (Kd) of an analogue was calculated from at least three (n ≥ 3) binding curves (Kd values) determined 
independently. The dissociation constant of human 125I-insulin was set to 0.3 nM.
Mouse embryonic fibroblasts (human IR-B isoform). Receptor binding studies with the insulin receptor in mem-
branes of mouse embryonic fibroblasts derived from IGF-1 receptor knock-out mice and that solely expressed 
the human IR-B isoform were performed as described in detail previously19. Binding data were analyzed and 
the dissociation constant (Kd) was determined with GraphPad Prism 5 software using a method of non-linear 
regression and a one-site fitting program and taking into account potential depletion of free ligand. Kd values of 
analogues were determined by the same procedure as for IR-A. The dissociation constant of human 125I-insulin 
was set to 0.3 nM.
Mouse embryonic fibroblasts (human IGF-1R). Receptor binding studies with the IGF-1 receptor in membranes 
of mouse embryonic fibroblasts derived from IGF-1R knock-out mice and transfected with human IGF-1R were 
performed as described previously52. Binding data were analyzed and the dissociation constants determined by 
the same method as for IR-B. The dissociation constant of human 125I-IGF-1 was set to 0.2 nM. Mouse embryonic 
fibroblasts expressing human IR-B or IGF-1R were a kind gift of Prof. Antonino Belfiore (University of Magna 
Grecia, Catanzaro, Italy) and Prof. Renato Baserga (Thomas Jefferson University, Philadelphia, PA, USA).
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